Efficacy and safety of mometasone furoate/formoterol combination in patients with bronchial asthma

Abstract

Studies carried out in different countries of the world revealed inadequate asthma control in clinical practice. [1--3] For example, in 56% of Russian patients who seek medical aid of specialists and GPs the disease is not controlled. [4] The data suggests that BA therapy needs to be improved. One of the most widely used treatments are inhaled corticosteroids (ICS) in combination with long-acting beta-adrenoceptor agonists (LABA). Global and national guidelines suggest using ICS/LABA at 3, 4 and 5th stages of asthma therapy. [5, 6] The article tells about a fixed combination containing formoterol and mometasone furoate (Zenheyl). The metered dose inhaler (MDIs, 50/5, 100/5 and 200/5 mcg) in aerosol form with dose counter is registered in Russia and other countries for the treatment of patients aged 12 years and older.

Keywords

• бронхиальная астма
• комбинированная терапия
• мометазона фуроат
• формотерол
• bronchial asthma
• combination treatment
• mometasone furoate
• formoterol